Patents by Inventor Carl Eric SCHWARTZ

Carl Eric SCHWARTZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK2 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20230121337
    Abstract: The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compounds and compositions in the treatment of various disorders related to CDK2 activity.
    Type: Application
    Filed: June 24, 2022
    Publication date: April 20, 2023
    Inventors: Louise Clare Kirman, Carl Eric Schwartz, Wojtek Michowski, Dale A. Porter, JR., Justin Ripper, John Feutrill
  • CDK2 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20230109076
    Abstract: The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 6, 2023
    Inventors: Louise Clare KIRMAN, Carl Eric SCHWARTZ, Wojtek MICHOWSKI, Dale A. PORTER, Justin RIPPER, John FEUTRILL, John Paul SHERRILL, Thomas P. BLAISDELL
  • Isoxazole carboxamides as irreversible SMYD inhibitors
    Patent number: 10669243
    Abstract: The present disclosure provides provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: June 2, 2020
    Assignee: EPIZYME, INC.
    Inventors: Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Jennifer C. Petter, Carl Eric Schwartz
  • Isoxazole Carboxamides as Irreversible SMYD Inhibitors
    Publication number: 20190241529
    Abstract: The present disclosure provides provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: January 11, 2019
    Publication date: August 8, 2019
    Applicant: EPIZYME, INC.
    Inventors: Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Jennifer C. Petter, Carl Eric Schwartz
  • Isoxazole carboxamides as irreversible SMYD inhibitors
    Patent number: 10179773
    Abstract: The present disclosure provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: January 15, 2019
    Assignee: EPIZYME, INC.
    Inventors: Richard Chesworth, Megan Alene Cloonan Foley, Kevin Wayne Kuntz, Lorna Helen Mitchell, Jennifer C. Petter, Carl Eric Schwartz
  • Isoxazole Carboxamides as Irreversible SMYD Inhibitors
    Publication number: 20180230110
    Abstract: The present disclosure provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: September 9, 2015
    Publication date: August 16, 2018
    Applicant: EPIZYME, INC.
    Inventors: Richard CHESWORTH, Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, Lorna Helen MITCHELL, Russell C. PETTER, Carl Eric SCHWARTZ